Clinical trial
Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML
NCT00363974 · Aegera Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00363974 |
|---|---|
| Title | Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML |
| Official title | An Open-Label Phase I/II Study of XIAP Antisense AEG35156 Administered to Patients With Refractory/Relapsed AML in Combination With Chemotherapy |
| Lead sponsor | Aegera Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelomonocytic, Acute |
| Intervention type | Drug |
| Interventions | XIAP antisense |
| Enrollment | 54 |
| Start date | Oct 1, 2005 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Aug 15, 2006 |
| Last update posted | Dec 1, 2009 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: